Drug Trial Radar · NCT07295678
URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Jan 5, 2026
Primary completion
Jul 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- CEN BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Eurofins Dermscan Pharmascan; URGO Recherche, Innovation et Développement
- First posted
- Dec 19, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to determine whether URGO FilmoCream Eczema is effective as a non-steroidal treatment to relieve symptoms of atopic dermatitis. It also aims to evaluate the cream's ability to moisturize, soothe irritation, protect the skin, and promote healing of eczema lesions. The main questions the study seeks to answer are: 1. Does URGO FilmoCream Eczema improve symptom relief of atopic dermatitis when used alongside standard topical corticosteroid treatment? 2. How do eczema lesions treated with topical corticosteroids alone progress and heal compared to those treated with topical corticosteroids plus URGO FilmoCream Eczema? To investigate this, patients with at least two similar eczema lesions are enrolled. One lesion is treated with topical corticosteroids alone, while the other is treated with topical corticosteroids plus URGO FilmoCream Eczema. The progression of both lesions is monitored throughout treatment, until healing, and for 28 days after the last application of topical corticosteroids.
Conditions
- Atopic Dermatitis
Interventions
Treatment period with dermocorticoid aloneDrug
Until lesion resolution, for a maximum of 30 consecutive days Treatment with dermocorticoids - desonide 0.1%, or betamethasone 0.05% in case treatment escalation is required.
Treatment period with combination of URGO FilmoCream Eczema and dermocorticoidCombination product
Until lesion resolution, for a maximum of 30 consecutive days URGO FilmoCream Eczema is applied at least twice daily (morning and evening) in a thin layer over the entire surface of the selected lesion, extending 1 cm beyond the edges, and left to dry for about 30 seconds to form a protective film. Reapplication is allowed if the film is disturbed (e.g., due to water exposure), with a maximum of 20 pump pressures per day. In the evening, it is applied after the dermocorticoid - desonide 0.1%, or betamethasone 0.05% in case treatment escalation is required.
Follow-up period after treatment with URGO Filmocream Eczema associated with dermocorticoidCombination product
During the 28-day follow-up period, in case of relapse, URGO FilmoCream Eczema is reapplied twice daily (morning and evening). If there is no improvement or worsening, the combined treatment must be reinitiated under the same conditions as during the treatment period.
Follow-up period after dermocorticoid treatment aloneDrug
During the 28-day follow-up period, in case of relapse, start with desonide 0.1%, escalate to betamethasone 0.05% if necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in local SCORAD Index at end of treatmentTime frame: up to 30 days
- Change from baseline in local SCORAD Index at 3 daysTime frame: 3 days
- Change from baseline in local SCORAD Index at 7 daysTime frame: 7 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eurofins Dermscan Poland
Gdansk, Poland
Private Practice
Malbork, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.